Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDE225 in Nevoid Basal Cell Carcinoma Syndrome
NCT01350115Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2011
- Primary completion
- Oct 2012
- Modality
- Allosteric Modulators
- Countries
- 4
01
Overview
A Phase 2 trial of sonidegib in nevoid basal cell carcinoma syndrome (NBCCS), sponsored by Novartis. Started Apr 2011; status: completed.
02
Drugs
sonidegib
03
Conditions
nevoid basal cell carcinoma syndrome (NBCCS)
Beyond the preview
Go deeper on NCT01350115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01350115.